Policy Paper

Biopharmaceutical Companies Driving Personalized Medicine

PhRMA May 20, 2015

The last five years have been characterized by increased momentum in personalized medicine. As scientific understanding has grown, and tools and technologies have advanced, more personalized medicines are progressing through development and reaching patients. New research sponsored by the Personalized Medicine Coalition and conducted by the Tufts Center for the Study of Drug Development (CSDD) updates a 2010 study, confirming that the biopharmaceutical sector is making significant progress but faces scientific, regulatory and reimbursement barriers as well as challenges regarding clinical adoption in its efforts to get targeted therapies through development and to patients.